CN115702154A - 一种嘧啶类化合物的盐和晶型及其制备方法 - Google Patents

一种嘧啶类化合物的盐和晶型及其制备方法 Download PDF

Info

Publication number
CN115702154A
CN115702154A CN202180038857.0A CN202180038857A CN115702154A CN 115702154 A CN115702154 A CN 115702154A CN 202180038857 A CN202180038857 A CN 202180038857A CN 115702154 A CN115702154 A CN 115702154A
Authority
CN
China
Prior art keywords
compound
fumarate
xrpd pattern
diffraction peaks
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180038857.0A
Other languages
English (en)
Inventor
宫正
李宏名
易仕东
李龙
王天明
陈平运
杨成喜
王涛
宋窈瑶
周江峰
梁玉峰
陈忠辉
田强
宋宏梅
薛彤彤
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN115702154A publication Critical patent/CN115702154A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

提供一种嘧啶类化合物的盐和晶型及其制备方法。具体而言，提供化合物I的盐和晶型，包括所述盐的晶型，以及它们的制备方法。
Figure DDA0003968135510000011

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202180038857.0A 2020-07-28 2021-07-23 一种嘧啶类化合物的盐和晶型及其制备方法 Pending CN115702154A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010737039 2020-07-28
CN2020107370397 2020-07-28
PCT/CN2021/108032 WO2022022398A1 (zh) 2020-07-28 2021-07-23 一种嘧啶类化合物的盐和晶型及其制备方法

Publications (1)

Publication Number Publication Date
CN115702154A true CN115702154A (zh) 2023-02-14

Family

ID=80037147

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180038857.0A Pending CN115702154A (zh) 2020-07-28 2021-07-23 一种嘧啶类化合物的盐和晶型及其制备方法

Country Status (7)

Country Link
US (1) US20230295174A1 (zh)
EP (1) EP4190781A4 (zh)
JP (1) JP2023535361A (zh)
KR (1) KR20230044358A (zh)
CN (1) CN115702154A (zh)
BR (1) BR112023000065A2 (zh)
WO (1) WO2022022398A1 (zh)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831216A2 (en) * 2004-12-23 2007-09-12 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
CA2992586A1 (en) * 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US11168090B2 (en) * 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
US20220017539A1 (en) * 2018-12-06 2022-01-20 Shenzhen Targetrx, Inc. Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof
CN111285882B (zh) * 2018-12-07 2022-12-02 四川科伦博泰生物医药股份有限公司 稠环化合物、包含其的药物组合物及其制备方法和用途
CA3130245A1 (en) * 2019-02-19 2020-08-27 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof

Also Published As

Publication number Publication date
KR20230044358A (ko) 2023-04-04
EP4190781A4 (en) 2023-12-27
JP2023535361A (ja) 2023-08-17
BR112023000065A2 (pt) 2023-01-31
WO2022022398A1 (zh) 2022-02-03
EP4190781A1 (en) 2023-06-07
US20230295174A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
EP3013835B1 (en) Solid forms of a macrocyclic kinase inhibitor
TWI729530B (zh) 吡咯并〔２，３－ｄ〕嘧啶甲苯磺酸鹽類、其晶形以及其製造方法及中間體
US11040979B2 (en) Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
EP3546460B1 (en) Pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, preparation method and use thereof
JP6986032B2 (ja) Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶
EP3327014A1 (en) Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
US20180230147A1 (en) Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor
TWI786303B (zh) 抑制ｃｄｋ4/6活性化合物的晶型及其應用
WO2022042712A1 (zh) Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途
JP7329510B2 (ja) ピラゾロピリジノン化合物
CN110950847B (zh) 氘代azd9291化合物的新晶型及其用途
CN108558865B (zh) 一种以吡啶并[2,3-d]嘧啶结构为母核的衍生物及其制备方法和应用
CN110551142A (zh) 一种稠环嘧啶类化合物的盐、晶型及其制备方法和应用
CN115175902A (zh) 一类用作激酶抑制剂的化合物及其应用
WO2021063335A1 (zh) Erk1/2蛋白激酶抑制剂及其用途
CN114008027A (zh) 二氨基嘧啶类化合物的盐、其固体形式及其制备方法和用途
CN115702154A (zh) 一种嘧啶类化合物的盐和晶型及其制备方法
EP3543227B1 (en) Fgfr4 inhibitor and preparation method and use thereof
KR20200097771A (ko) Akt 억제제로서의 염 형태 및 이의 결정 형태
KR20230154243A (ko) 불소-치환된 피리도피라졸계 화합물의 결정형 및 이의 제조 방법
WO2023041026A1 (zh) Rho相关蛋白激酶抑制剂或其溶剂合物的固体形式及其制备方法和用途
WO2023246858A1 (zh) 一种硼酸酯衍生物的可药用盐、其结晶形式及用途
JP2023551892A (ja) カゼインキナーゼ１ε阻害剤の結晶形、製造方法及びその使用
KR20220159457A (ko) Fgfr4 억제제의 염 형태, 결정 형태 및 그 용도
CN114478547A (zh) 固体形式的布鲁顿酪氨酸激酶抑制剂化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083712

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination